“…For example, the Federal Food and Drug Administration (FDA) has endorsed the use of CCS as a primary efficacy endpoint in prodromal AD clinical trials as long as they combine both cognitive and functional measures ( Hoogendam et al, 2014 ). CCS derived from neuropsychological test batteries consist of statistically related measures within that battery ( Alavi et al, 2020 ; Salih Hasan & Abdulazeez, 2021 ; Schneider & Goldberg, 2020 ). The CCS are then given names that represent specific cognitive processes or domains, such as learning and memory, visuospatial abilities, executive function (EF), language, attention and processing speed (which are sometimes included within EF), and intelligence ( Arango-Lasprilla et al, 2017 ; Baek et al, 2012 ; Harp et al, 2021 ; Harrison, 2019 ; Harvey, 2019 ; Hayat et al, 2021 ; Hubley, 2010 ; Lambert et al, 2018 ; Millan et al, 2012 ; Perry et al, 2017 ; Riordan, 2017 ; Schumacher et al, 2019 ; Smits et al, 2015 ; Vigliecca, 2021 ; Wessels et al, 2015 ).…”